Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024

Biofrontera

13/11/2025 13:25

Overview

Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024

Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates

Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments

Outlook

Company anticipates substantial 4Q25 and annual revenue growth due to price normalization

Biofrontera expects enhanced margins from new Ameluz and RhodoLED royalty structure

Company sees potential FDA approval for Ameluz in new indications, expanding market opportunities

Result Drivers

ADVANCED PURCHASES - Q3 revenue decline attributed to advanced purchases in 2024 ahead of price increase

ASSET ACQUISITION - Purchase of Ameluz and RhodoLED assets expected to enhance margins and profitability

COMMERCIAL STRATEGY - Revamped sales strategy and customer segmentation proving effective

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$7 mln
$9 mln (2 Analysts)
Q3 Net Income
-$6.60 mln
Q3 Adjusted EBITDA
Miss
-$6 mln
-$2.60 mln (1 Analyst)
Q3 Operating Expenses
$13.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 83.8% above its November 12 closing price of $0.97

Press Release: ID:nGNX557l71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)